Collegium Pharmaceutical, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-12-31 was $315.00K, a 76.19% decline year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-09-30 was $108.00K, a 80.00% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-12-31 was $1.32M.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was $60.00K.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $4.51M, a 33.94% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $6.83M, a 42.77% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $4.79M, a 21.38% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $3.94M, a 38.93% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.51M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $6.83M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $4.79M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $3.94M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $6.46M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $423.00K derived: sum of 2 quarters · filed 2023-02-23 | $7.52M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.20M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $7.09M 10-Q · filed 2020-08-05 | |||
| 2019-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.38M derived: sum of 2 quarters · filed 2022-02-24 | $1.51M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $183.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $123.00K 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $3.97M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $1.10M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |